Cardiovascular Risks of Fluphenazine in a Patient With Schizophrenia
نویسندگان
چکیده
منابع مشابه
Fluphenazine Decanoate in Chronic Schizophrenia
Introduction of chlorpromazine by Delay and Danikcr in 1952 revolutionized the treatment of acute schizophrenia. However, chronic form of the illness still remains a challenge, mainly because of noncompliance of the patients with the therapeutic regimen (Diamond and Marks, 1960; Olson and Peterson, 1960; Hare and Willcox, 1967 ; Wilson and Enoch, 1967 and Ayd, 1975). Another factor is the errat...
متن کاملsecuritization of mortality risks in life annuities
insurers have in the past few decades faced longevity risks - the risk that annuitants survive more than expected - and therefore need a new approach to manage this new risk. in this dissertation we survey methods that hedge longevity risks. these methods use securitization to manage risk, so using modern financial and insurance pricing models, especially wang transform and actuarial concepts, ...
15 صفحه اولThe wandering of families with schizophrenia patient in a challenging support system and covid 19 crisis
Introduction: schizophrenia is a chronic condition that leads to debilitating consequences, is associated numerous challenges. So families need long-term psychosocial support. Methods: the study was performed by interpretive descriptive method. Using purposive sampling, 30 participants participated in the study. Data were collected through individual interviews and coded, codes with similar the...
متن کاملTreatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
OBJECTIVE This study compares 3 cohorts of patients with schizophrenia before, during, and after initiating treatment with fluphenazine decanoate (FD), haloperidol decanoate (HD), or long-acting injectable risperidone (LAR). METHODS Administrative data are analyzed from California Medicaid (Medi-Cal) beneficiaries with schizophrenia who initiated FD, HD, or LAR treatment. Patients were requir...
متن کاملFluphenazine (oral) versus placebo for schizophrenia.
Fluphenazine, a phenothiazine derivative, was one of the first drugs to be classed as an "antipsychotic" and was approved by the Food and Drug Administration in 1959. In Britain, it was first used for the relief of anxiety. The American reports, however, were the first to indicate its value in psychotic illness. Fluphenazine is an inexpensive and widely accessible antipsychotic drug that has be...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Pharmacy Technology
سال: 2018
ISSN: 8755-1225,1549-4810
DOI: 10.1177/8755122518771269